
Keywords: آنتی بادی های انفلایسیماب; CD; Immunogenicity; Monitoring Therapy; Ulcerative Colitis; ATI; antibodies to infliximab; CD; Crohn's disease; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; HMSA; homogeneous mobility shift assay; HR; hazard ratio; IBD; inflammator